PriceTargets.com logo

NASDAQ:IMPL - Impel Pharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $55.00
  • Forecasted Upside: 511.11 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$9.00 As of 07/5/2022 11:10 AM ET
▼ -0.22 (-2.39%)

This chart shows the closing price for IMPL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Impel Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMPL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMPL

Analyst Price Target is $55.00
▲ +511.11% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Impel Pharmaceuticals in the last 3 months. The average price target is $55.00, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 511.11% upside from the last price of $9.00.

This chart shows the closing price for IMPL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 polled investment analysts is to buy stock in Impel Pharmaceuticals.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/10/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/10/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/9/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/7/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/5/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/5/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/4/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/4/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/3/2021CowenBoost Price TargetOutperform$35.00 ➝ $55.00High
5/18/2021CowenInitiated CoverageOutperform$35.00Low
5/18/2021WedbushInitiated CoverageOutperform$21.00Low
5/18/2021GuggenheimInitiated CoverageBuy$32.00Low
(Data available from 7/5/2017 forward)

News Sentiment Rating

-0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
12/7/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/6/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/5/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/7/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
4/6/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
5/6/2022
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
6/5/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/5/2022

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

  • No very positive mentions tracked during this time.
Impel Pharmaceuticals logo
Impel NeuroPharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel NeuroPharma, Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $9.00
Low: $9.00
High: $9.00

50 Day Range

MA: $7.57
Low: $5.83
High: $10.12

52 Week Range

Now: $9.00
Low: $5.72
High: $34.75

Volume

6 shs

Average Volume

105,856 shs

Market Capitalization

$208.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Impel Pharmaceuticals?

The following Wall Street research analysts have issued stock ratings on Impel Pharmaceuticals in the last twelve months: Cowen Inc.
View the latest analyst ratings for IMPL.

What is the current price target for Impel Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Impel Pharmaceuticals in the last year. Their average twelve-month price target is $55.00, suggesting a possible upside of 511.1%.
View the latest price targets for IMPL.

What is the current consensus analyst rating for Impel Pharmaceuticals?

Impel Pharmaceuticals currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IMPL will outperform the market and that investors should add to their positions of Impel Pharmaceuticals.
View the latest ratings for IMPL.

How do I contact Impel Pharmaceuticals' investor relations team?

The company's listed phone number is 206-568-1466. The official website for Impel Pharmaceuticals is www.Impelnp.com. Learn More about contacing Impel Pharmaceuticals investor relations.